Tuberculosis
Multidrug Resistant Tuberculosis: Market Insights, 2020-2030 [Upcoming Report]
-
Lowest Price Guaranteed
From USD
4,899
-
-
-
-
The ‘Multi-drug Resistant Tuberculosis Market, 2020-2030’ report features comprehensive insights about the current market landscape consisting of several industry stakeholders engaged in developing disease modifying interventions, drug products and therapies that have been developed / are being developed for the treatment of condition as well as the market trends across various geographical regions (North America, Europe and Asia-Pacific).
This report provides an informed opinion on the likely adoption of therapeutics designed to treat multi-drug resistant tuberculosis. It features an in-depth analysis, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product’s mechanism of action, dosage and administration, and pharmacological studies, regulatory milestones, and other development activities.
One of the key objectives of the report was to estimate the existing market size and the future opportunity of therapies for multi-drug resistant tuberculosis, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of the forecasted therapies and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market for the period 2020-2030.
Scope of the Report
- A detailed assessment of the therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and mechanism of action across the complete product development cycle, including all clinical and nonclinical stages.
- Detailed profiles of the players that are engaged in the development of therapies for multi-drug resistant tuberculosis, featuring overview of the company, its financial information (if available), a description of its product portfolio, recent collaborations and an informed future outlook.
- An analysis of scientific articles published since 2015, highlighting the research focus within this industry segment.
- A detailed clinical trial analysis of completed, ongoing and planned studies of various therapies, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, enrolled patient population and regional distribution of trials, type of drug molecule, phase of development, study design, leading industry and non-industry players (in terms of number of trials conducted), study focus, target therapeutic area, key indications, and clinical endpoints.
- An analysis of the partnerships that have been established in the domain, over the last five years, covering research agreements, product / technology licensing agreements, mergers / acquisitions, asset purchase agreements, R&D and commercialization agreements, IP licensing agreements, clinical trial agreements, product development agreements, and other relevant deals.
- An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, by companies that are engaged in this field.
Key Questions Answered
- What are the prevalent R&D trends related to multi-drug resistant tuberculosis?
- What are the key challenges faced by stakeholders engaged in this domain?
- What are the principal therapies developed by the companies in this domain?
- Who are the leading industry and non-industry players in this market?
- What are the contributions of big pharma players in this field?
- What are the key geographies where research on multi-drug resistant tuberculosis is being conducted?
- Who are the key investors in this domain?
- What kind of partnership models are commonly adopted by industry stakeholders?
- What are the factors that are likely to influence the evolution of this upcoming market?
- How is the current and future market opportunity likely to be distributed across key market segments?